tetano
Editor, Senior Moderator
Vaccines (Basel). 2019 Aug 12;7(3). pii: E87. doi: 10.3390/vaccines7030087.
[h=1]Comparative Immunogenicity of the 2014-2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children.[/h] Ang JC[SUP]1[/SUP], Wang B[SUP]2[/SUP], Wang JJF[SUP]1[/SUP], Zeng PYF[SUP]1[/SUP], Krammer F[SUP]3[/SUP], Ward BJ[SUP]4[/SUP], Russell ML[SUP]5[/SUP], Loeb M[SUP]6[/SUP], Miller MS[SUP]7[/SUP].
[h=3]Author information[/h] 1 Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. 2 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 4 Research Institute of McGill University Health Centre, Montreal, QC H3H 2R9, Canada. 5 Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada. 6 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada. loebm@mcmaster.ca. 7 Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. mmiller@mcmaster.ca.
[h=3]Abstract[/h] Both inactivated influenza vaccines (IIV) and live-attenuated influenza vaccines (LAIV) have been recommended for administration to children. Children are a high-risk group for severe influenza, and a major source of transmission. Therefore, prevention of infection by vaccination is particularly important. However, efficacy and immunogenicity of these vaccines are known to vary by season and geographic location. We compared the immunogenicity of the 2014-2015 Northern Hemisphere trivalent IIV and LAIV against influenza A virus in Canadian Hutterite children aged 2 to 17 using hemagglutination inhibition (HAI) assays, and enzyme-linked immunosorbent assays to measure hemagglutinin-specific serum IgA and mucosal IgA. Both vaccine formulations induced significant increases in HAI titers against H1N1 and H3N2 vaccine strains. Serum IgA titers against H3N2 were significantly boosted by both IIV and LAIV, while only IIV induced a significant increase in serum IgA specific to the H1N1 vaccine strain. While HAI titers correlated with protection conferred by IIV, mucosal IgA titers correlated with protection conferred by LAIV (mucosal IgA titers could not be established as a correlate for IIV due to sample size limitations). IIV and LAIV were previously reported to be equally efficacious in this cohort, although the immunogenicity of IIV was generally superior.
[h=4]KEYWORDS:[/h] antibodies; childhood vaccination; correlates of protection; hemagglutinination inhibition; inactivated influenza vaccine; influenza virus; live-attenuated influenza vaccine; mucosal IgA
PMID: 31408963 DOI: 10.3390/vaccines7030087
Free full text
[h=1]Comparative Immunogenicity of the 2014-2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children.[/h] Ang JC[SUP]1[/SUP], Wang B[SUP]2[/SUP], Wang JJF[SUP]1[/SUP], Zeng PYF[SUP]1[/SUP], Krammer F[SUP]3[/SUP], Ward BJ[SUP]4[/SUP], Russell ML[SUP]5[/SUP], Loeb M[SUP]6[/SUP], Miller MS[SUP]7[/SUP].
[h=3]Author information[/h] 1 Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. 2 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada. 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 4 Research Institute of McGill University Health Centre, Montreal, QC H3H 2R9, Canada. 5 Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada. 6 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada. loebm@mcmaster.ca. 7 Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. mmiller@mcmaster.ca.
[h=3]Abstract[/h] Both inactivated influenza vaccines (IIV) and live-attenuated influenza vaccines (LAIV) have been recommended for administration to children. Children are a high-risk group for severe influenza, and a major source of transmission. Therefore, prevention of infection by vaccination is particularly important. However, efficacy and immunogenicity of these vaccines are known to vary by season and geographic location. We compared the immunogenicity of the 2014-2015 Northern Hemisphere trivalent IIV and LAIV against influenza A virus in Canadian Hutterite children aged 2 to 17 using hemagglutination inhibition (HAI) assays, and enzyme-linked immunosorbent assays to measure hemagglutinin-specific serum IgA and mucosal IgA. Both vaccine formulations induced significant increases in HAI titers against H1N1 and H3N2 vaccine strains. Serum IgA titers against H3N2 were significantly boosted by both IIV and LAIV, while only IIV induced a significant increase in serum IgA specific to the H1N1 vaccine strain. While HAI titers correlated with protection conferred by IIV, mucosal IgA titers correlated with protection conferred by LAIV (mucosal IgA titers could not be established as a correlate for IIV due to sample size limitations). IIV and LAIV were previously reported to be equally efficacious in this cohort, although the immunogenicity of IIV was generally superior.
[h=4]KEYWORDS:[/h] antibodies; childhood vaccination; correlates of protection; hemagglutinination inhibition; inactivated influenza vaccine; influenza virus; live-attenuated influenza vaccine; mucosal IgA
PMID: 31408963 DOI: 10.3390/vaccines7030087
Free full text